Navigation Links
Topline Results of Phase III Study in Acute Ischemic Stroke,(Dias-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo

NEW YORK, May 31, 2007 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. and PAION AG today announced topline results of the DIAS-2 (Desmoteplase In Acute Ischemic Stroke) study with the compound Desmoteplase. The Phase III study was designed to investigate the improvement of clinical outcome in patients with acute ischemic stroke treated with Desmoteplase within 3 to 9 hours after onset of stroke symptoms as compared to placebo. The primary efficacy endpoint (difference between active treatment and placebo in percentage of composite responders as defined below) was not met. The blinded, randomized, placebo-controlled, dose-ranging trial was jointly conducted by PAION and Forest Laboratories, Inc., and enrolled a total of 186 patients in Europe, USA, Canada, Australia, Hong Kong and Singapore. Forest Laboratories, Inc. is the partner of PAION for Desmoteplase for North America and H. Lundbeck A/S is PAION's partner for the rest of the world.

In this study, patients received either placebo (N=63), 90 mcg/kg (N=57), or 125 mcg/kg (N=66) of Desmoteplase as an intravenous bolus within 3-9 hours after the onset of stroke. Patients were eligible for treatment only in case of a distinct penumbra of at least 20% (insufficiently perfused but still salvageable tissue area around the primary location of stroke), which was confirmed by magnetic resonance imaging (MRI) or perfusion computed tomography (pCT).

The primary efficacy endpoint in the study was clinical improvement at Day 90 defined for each patient as achievement of all three of the following criteria; (1): Improvement of greater than or equal to 8 points from baseline on the National Institutes of Health Stroke Scale (NIHSS) or NIHSS score less than or equal to 1, (2): Modified Rankin Scale (MRS) score of 0-2, and (3): Barthel Index (BI) score of 75-100. Only patients who simultaneously met the criteria along all three scales were considered resp
'"/>




Page: 1 2 3 4

Related medicine technology :

1. deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack
2. CombinatoRx Provides Topline Results from Phase 2 RA Study with CRx-139 and Very Low Dose Prednisolone
3. CV Therapeutics Announces Topline MERLIN TIMI-36 Results
4. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
5. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
6. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
7. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
9. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:7/2/2015)... , June 25, 2015 ... of the "Veterinary / Animal Vaccines Market by ... report to their offering. The global ... by 2020 from $5,507.3 Million in 2015, at a ... Major factors fueling market growth are growing prevalence of ...
(Date:7/2/2015)... ATLANTA , July 2, 2015 Legal-Bay ... U.S. District Judge Joseph Goodwin in the ... (VA) consolidated 26 transvaginal mesh cases against Ethicon for ... nd . The cases for the 26 women include ... by a device made my Johnson & Johnson,s Ethicon ...
(Date:7/2/2015)... Agreement reinforces ...   ViiV Healthcare and Desano Pharmaceuticals (Desano) ... China of dolutegravir. The agreement will ... (API), and will allow ViiV Healthcare to offer a competitive ... name Tivicay®) for China and a ...
Breaking Medicine Technology:Veterinary / Animal Vaccines Market 2015 - Global Forecast to 2020 for the $7.19 Billion Industry 2Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 2Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 3ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 2ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 3ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 4ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 5ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 6
... and AMSTERDAM , July 15, 2010 ... company,CEO Dr. Bernhard Sixt will provide testimony at ... D.C. on the federal regulation of laboratory developed tests,(LDTs). ... for Devices and Radiological Health (CDRH), the Public Meeting on,Oversight ...
... BROOK, N.J. and BASEL, Switzerland , July ... agreement for the scale-up and commercial production of Anthim, a ... inhaled anthrax. Under the new contract, Lonza will provide process ... its facilities in the USA . The manufacturing process ...
Cached Medicine Technology:Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests 2Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development 2Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development 3Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development 4
(Date:7/2/2015)... ... July 02, 2015 , ... Global leader and compression ... compression socks designed for men. , For style that’s quick on its feet, ... routine. This is great news for men everywhere because a simple change in socks ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... provides comprehensive information on the pipeline products with comparative analysis of the ... therapy (NPWT) with 22 market data tables and 4 figures, spread across ...
(Date:7/2/2015)... ... July 02, 2015 , ... Breakthrough ... wrist pain treatment. Dr. Lev Kalika, founder of New York Dynamic Neuromuscular ... authority on the conservative treatment of back, hip, knee and shoulder pain as ...
(Date:7/2/2015)... , ... July 02, 2015 , ... Hand sanitizers have ... current summer flu season, according to fresh water advocate and radio host Sharon Kleyne, ... hands. Kleyne cautions that for maximum effectiveness, hand sanitizers must be applied correctly and ...
(Date:7/2/2015)... ... July 02, 2015 , ... The report summarizes key statistics ... report is a valuable source of guidance and direction for companies and individuals ... for the Gelatin Capsule industry including capacity, production, production value, cost and profit, ...
Breaking Medicine News(10 mins):Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 2Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 4Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 2Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 4
... Farms, a national,ground beef producer, is issuing a voluntary ... N.Y., facility and sold through Price,Chopper, Shaw,s, BJ,s, and ... affected product may contain small pieces of hard plastic. ... 05/15/08, or a,"Julian date 124" on the package,s label. ...
... 12 MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ) today ... 2008., The net loss for the first quarter ... million during the same period in 2007. As of,March ... investments of $81.1 million., First Quarter Financial Results, ...
... prevented heart failure in those with Duchenne muscular dystrophy ... Duchenne muscular dystrophy often suffer from heart failure, but ... condition, a new Canadian study finds. , In experiments ... performance by preventing the breakdown of a compound called ...
... WASHINGTON, May 12 Most baby boomers say,they ... to a,new survey conducted by Harris Interactive on ... would have difficulty paying bills and,many would have ... disability,occurred., (Logo: http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ), ...
... Effective May 19, the Texas,Hospital Association will have a ... 1108 Lavaca, located within steps of the Texas Capitol., ... Association,and a group of investors, THA was able to ... our members," said Dan Stultz, M.D., FACP, FACHE,president/CEO of ...
... MONTREAL, May 12 /PRNewswire-FirstCall/ - CryoCath(R) Technologies,Inc., the ... announced financial results for the second quarter,ended March 31, ... Highlights:, - Accelerated revenue growth in ... increase over comparable electrophysiology (EP) ...
Cached Medicine News:Health News:Fairbank Farms Issues Voluntary Recall for Selected Ground Beef Products 2Health News:MAP Pharmaceuticals Reports First Quarter of 2008 Financial Results 2Health News:MAP Pharmaceuticals Reports First Quarter of 2008 Financial Results 3Health News:MAP Pharmaceuticals Reports First Quarter of 2008 Financial Results 4Health News:MAP Pharmaceuticals Reports First Quarter of 2008 Financial Results 5Health News:Viagra May Protect Hearts of Some Muscular Dystrophy Patients 2Health News:Most Baby Boomers are Financially Unprepared for a Potential Disability 2Health News:Hospital Association Moves Headquarters to Downtown Austin 2Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 2Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 3Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 4Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 5Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 6Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 7Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 8Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 9Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 10Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 11Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 12
... Airial Handheld Ultrasonic Nebulizer has ... This compact, portable, and lightweight ... fast & quite treatments operating ... or DC auto adapter. , ...
With ten colors available, Spectrums line of Color-Coded Fiberoptic Light Cables makes it easy to track by department....
Lumitex® LightMat® Surgical Illuminator improves visualization in deep cavity surgery. Flexible and malleable, it attaches easily to most retractors, bringing bright, cool area lighting where...
... the exceptional performance you need at a price ... and durability youd expect from headlights priced much ... features our thinnest cable and adjusts from 90 ... when you reach for a headlight you can ...
Medicine Products: